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Abstract
Mechanical disruption of atherosclerotic plaques at the time 
of percutaneous coronary intervention (PCI) is a potent stimu-
lus for arterial thrombosis. Since platelets play a crucial role in 
the cascade of clot formation, platelet inhibition is an essen-
tial step for successful PCI. Aspirin remains the cornerstone of 
any antithrombotic regimen in the interventional setting. The 
addition of a thienopyridine is mandatory following stenting 
to prevent thrombosis of the device. Whenever possible, pa-
tients undergoing PCI should be pretreated with clopidogrel 
and the drug should be continued for up to 1 year. Glycoprotein 
IIb/IIIa antagonists should be administered in high-risk pa-
tients, such as those with acute coronary syndromes, diabetes, 
or complex coronary anatomy.
Plättchenhemmung bei perkutanen Koronarinterventionen 
Zusammenfassung
Das mechanische Trauma der Gefäßwand durch Ballonangio-
plastie oder Stenteinlage ist ein starker Stimulus für eine Ko-
ronarthrombose. Da die Plättchen eine entscheidende Rolle in 
der Gerinnselbildung spielen, ist die Plättchenhemmung ein 
essentieller Bestandteil der erfolgreichen perkutanen Koro-
narintervention. Aspirin bleibt der Eckpfeiler jeder antithrom-
botischen Therapie während perkutaner koronarer Interven-
tionen. Die Zugabe von Thienopyridinen ist nach Stenteinlage 
unabdingbar, um Stentthrombosen zu vermeiden. Wenn im-
mer möglich, sollte vor einer geplanten Intervention Clopi-
do grel verabreicht und die Therapie bis zu 1 Jahr nach dem 
Eingriff weitergeführt werden. Plättchen-Glykoprotein-IIb/
IIIa-Rezeptor-Antagonisten sollten bei Hochrisikopatienten 
verabreicht werden, wie Patienten mit akutem Koronarsyn-
drom, Diabetes oder komplexer Koronaranatomie.
Schlüsselwörter:  Aspirin · Clopidogrel · Plättchenhemmer · Glykoprotein-IIb/IIIa-Antagonisten · Akutes Koronarsyn-
drom · Diabetes · Perkutane Koronarintervention
Introduction
Spontaneous rupture of a coronary plaque as well as 
balloon catheter-based mechanical disruption may lead 
to exposure to the blood circulation of subendothelial 
thrombogenic material, triggering a well-orchestrated 
cascade of molecular events characterized by the inter-
actions between platelets, leukocytes, and the subendo-
thelium with subsequent activation of the coagulation 
system. This chain reaction may result in arterial throm-
bus formation and subsequent abrupt vessel closure or 
distal embolization. While the pathophysiological as-
pects of platelet activation and aggregation as well as 
the pharmacological basis of antiplatelet therapy have 
been discussed in detail in other contributions, the focus 
of the present report is to address platelet inhibition in 
percutaneous coronary intervention (PCI). The goal of 
antiplatelet therapy in this setting is to achieve a clini-
cally meaningful reduction of ischemic cardiac events 
while maintaining an acceptable rate of bleeding com-
plications. Three main classes of antiplatelet agents 
constitute the armamentarium of the interventionalist, 
including aspirin, the thienopyridines and the platelet 
Key Words:  Aspirin · Clopidogrel · Platelet inhibitors · Glycoprotein IIb/IIIa antagonists · Acute coronary syndromes · 
Diabetes · Percutaneous coronary intervention
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glycoprotein (GP) IIb/IIIa receptor inhibitors. The use 
of these drugs, alone or in combination, will be present-
ed with special attention to the three clinical settings of 
PCI application, namely stable coronary disease, non-ST 
segment elevation acute coronary syndromes (ACS), 
and acute myocardial infarction (MI).
Aspirin
Aspirin (acetylsalicylic acid) is the most widely used 
and cheap inhibitor of platelet function and remains 
the cornerstone of any antithrombotic therapy during 
PCI. Aspirin potently inhibits platelet aggregation in-
duced by arachidonic acid but is a relatively weak anti-
platelet agent following stimulation by a variety of 
other agonists, including adenosine diphosphate 
(ADP) and thrombin [1]. This observation sets the ba-
sis for combination strategies to target different plate-
let activation pathways. In the presence of serious aspi-
rin intolerance, the risks and benefits of PCI should be 
carefully weighed against alternative strategies (i.e., 
medical management, bypass surgery), since the safety 
of the procedure among patients not taking aspirin is 
unknown. Interestingly, initial investigations of aspirin 
for PCI were designed not to address its antiplatelet 
properties but its efficacy in restenosis prevention. Al-
though aspirin, like any other antiplatelet agents sub-
sequently tested, had no impact on restenosis, a reduc-
tion in ischemic events associated with the drug was 
documented. In an early study, 376 patients undergo-
ing coronary balloon angioplasty (PTCA) were ran-
domized to either aspirin (990 mg daily) and dipyri-
damole (225 mg daily) or placebo starting 24 h prior to 
the procedure and continuing for 4–7 months thereaf-
ter [2]. Among patients allocated to the antiplatelet 
combination the incidence of periprocedural Q-wave 
MI was reduced compared with controls (1.6% vs. 
6.9%; p = 0.011). The M-HEART II trial has been the 
only placebo-controlled study testing the efficacy of 
aspirin monotherapy following angioplasty [3]. All pa-
tients (n = 752) received aspirin 325 mg the day prior to 
PTCA. The aspirin group received 325 mg daily for 
6 months following PTCA, while the other group re-
ceived placebo. At 6 months, the allocation to anti-
platelet therapy was associated with a significant re-
duction in MI compared with controls (1.2% vs. 5.7%; 
p = 0.03). Since then, aspirin has invariably been used 
in all percutaneous revascularization procedures.
In the absence of randomized clinical trials, the op-
timal aspirin dose in the interventional setting remains 
unknown. The 2005 ESC-PCI guidelines support the 
use of aspirin in all patients (grade I C recommenda-
tion; Table 1) [4]. A loading dose of 500 mg orally > 3 h 
prior to or at least 300 mg intravenously at the time of 
PCI in all patients not on chronic treatment is recom-
mended. With respect to long-term use, doses > 100 mg 
daily are not recommended, since they do not appear to 
convey additional benefit and are associated with in-
creased bleeding risk.
Thienopyridines
Coronary stenting is considered the gold standard in 
PCI, since it decreases both acute (i.e., abrupt vessel clo-
sure) and long-term (i.e., restenosis) complications as-
sociated with balloon angioplasty [5]. Due to the intrin-
sic thrombogenicity of stainless-steel stents, the early 
coronary stent experience was burdened by an approxi-
mately 10% rate of acute or subacute stent thrombosis 
[6]. At that time, patients were treated with the combi-
nation aspirin and oral anticoagulants. The explo-
sive success of intracoronary stenting was only possible 
because of subsequent antiplatelet combination therapy 
with aspirin and thienopyridines, which led to a dramat-
ic reduction of subacute stent thrombosis (in the range 
of 1%) [7]. Ticlopidine and clopidogrel are the two thi-
enopyridines currently available for clinical use. Both 
agents are administered orally, have similar molecular 
structures and bind irreversibly to the P2Y12 purinocep-
tor on platelets inducing inhibition of ADP-mediated 
platelet aggregation [8]. Additionally, since this recep-
Table 1. Recommendation grading according to the European Society 
of Cardiology.
Tabelle 1. Einteilung der Empfehlungen gemäß den Richtlinien der 
Europäischen Gesellschaft für Kardiologie.
Level of recommendation
I  Evidence and/or general agreement that a given treatment is benefi-
cial, useful, and effective
II  Conflicting evidence and/or divergence of opinion about the useful-
ness/efficacy of the treatment
IIa Weight of evidence/opinion is in favor of usefulness/efficacy
IIb Usefulness/efficacy is less well established by evidence/opinion
Level of evidence
A Data derived from multiple randomized clinical trials or meta-analysis
B  Data derived from a single randomized clinical trial or large nonran-
domized studies
C  Consensus of opinion of the experts and/or small studies, retrospec-
tive studies, registries
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tor is involved in the amplification of platelet aggrega-
tion induced by other agonists such as thrombin, epi-
nephrine, or thromboxane A2, thienopyridines indirect-
ly inhibit platelet aggregation induced by these agonists 
[9]. A meta-analysis of registries and randomized trials 
comparing ticlopidine with clopidogrel in patients un-
dergoing coronary stenting suggested that clopidogrel 
was just as efficacious as ticlopidine and associated with 
fewer adverse drug effects [10]. Since ticlopidine may 
cause severe neutropenia in approximately 1% of pa-
tients and requires twice-daily administration, clopido-
grel virtually replaced it for all indications in most Euro-
pean countries and in the USA.
Both thienopyridines are prodrugs requiring first-pass 
metabolism in the liver to become biologically active and 
have therefore a slow onset of action. Following oral 
maintenance dose (2 × 250 mg/d for ticlopidine, 75 mg/d 
for clopidogrel) the platelet inhibition’s plateau is 
achieved after 3–5 days with ticlopidine and after 4–7 
days with clopidogrel. Until recently, the main indication 
for thienopyridine use was the prevention of subacute 
stent thrombosis and the drugs were administered fol-
lowing the procedure. The CREDO trial investigated 
whether clopidogrel administration before and prolonged 
after PCI was associated with a reduction in ischemic 
events [11]. The study enrolled a total of 2,116 patients 
that were randomized to 300 mg clopidogrel or placebo 
3–24 h prior to PCI. Thereafter, all patients received 
clopidogrel in the oral maintenance dose (75 mg/d) 
through day 28. From day 29 through 12 months, patients 
in the loading-dose group received clopidogrel, while 
those in the control group received placebo. Overall, 
clopidogrel pretreatment did not significantly reduce the 
composite endpoint of MI, death, or target-vessel revas-
cularization (TVR) at 28 days (p = 0.23). However, in the 
prespecified subgroup of patients who received the drug 
≥ 6 h prior to PCI a trend toward a benefit was observed 
(relative risk reduction 39%; p = 0.05).
In the PCI-CURE study, the investigators addressed 
the impact of the combination strategy among 2,658 pa-
tients with ACS undergoing PCI during index hospital-
ization according to the discretion of the treating physi-
cian [12]. Patients received the study drug for an average 
of 10 days prior to PCI. After intervention, both groups 
received open-label thienopyridines for 2–4 weeks, fol-
lowed by clopidogrel or placebo for a mean of 8 months. 
The primary endpoint was MI, urgent revascularization, 
or cardiovascular mortality. At 30 days, the clopido-
grel-pretreated group had a 30% relative risk reduction 
in events (p = 0.03). Recent investigations suggest that 
600 mg clopidogrel loading dose confers more potent 
platelet inhibition and shortens the time interval nec-
essary for effective pretreatment (Figure 1) [13, 14]. Be-
sides, administration of an additional loading dose (300–
600 mg) appears to provide further platelet inhibition in 
patients on clopidogrel maintenance dose (Figure 2) [15]. 
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Figure 1. Effect on platelet inhibition following oral loading doses (LD) 
of clopidogrel. Demonstrated is the platelet glycoprotein IIb/IIIa re-
ceptor activation following 2 µmol adenosine diphosphate (ADP) 
stimulus. *p < 0.001 and **p < 0.05 [13].
Abbildung 1. Plättchenhemmung nach Gabe von Clopidogrel per os. 
Dargestellt ist die Aktivierung des Glykoprotein-IIb/IIIa-Rezeptors 
nach Gabe von 2 µmol Adenosindiphosphat (ADP). *p < 0,001 und **p < 
0,05 [13].
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Figure 2. Maximal aggregation induced by 5 µmol/l adenosine diphos-
phate (ADP) before and 6 h after 600 mg clopidogrel loading in pa-
tients not pretreated and in those on chronic clopidogrel therapy. Indi-
vidual data are shown, along with mean (thick lines) and standard 
deviation (thin lines) [15].
Abbildung 2. Maximale Plättchenhemmung nach 5 µmol/l Adenosin-
diphosphat (ADP) vor und 6 h nach 600 mg Clopidogrel per os bei 
nicht vorbehandelten Patienten und bei Patienten unter chronischer 
Clopidogreltherapie [15].
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However, it is unknown whether to administer an addi-
tional bolus dose prior to PCI might translate into a re-
duction of ischemic events. Since no randomized com-
parison has addressed different clopidogrel regimens, the 
optimal clopidogrel loading dose and/or timing of treat-
ment cannot conclusively be defined.
The efficacy of prolonged dual antiplatelet therapy 
following PCI has been investigated in the CREDO [11] 
and the PCI-CURE trials [12]. In CREDO, the occur-
rence of MI, stroke, or death occurring between 30 days 
and 1 year was reduced by 37% (p = 0.04) with pro-
longed double antiplatelet therapy. A trend toward ma-
jor bleeding in the combination therapy was observed, 
while minor bleedings were similar. In the PCI-CURE 
study a benefit in terms of cardiovascular death, MI, or 
rehospitalization from clopidogrel from day 30 to 1 year 
was observed (risk ratio 0.86; p = 0.05). Clopidogrel did 
not increase major but only minor bleedings. Safety and 
efficacy of long-term dual antiplatelet therapy in 
high-risk patients are currently being tested in the CHA-
RISMA trial.
The 2005 ESC-PCI guidelines recommend the use 
of clopidogrel pretreatment with a loading dose of 300 
mg at least 6 h before (ideally the day before) planned 
PCI in stable coronary disease (grade I C) [4]. In pri-
mary PCI for ST segment elevation MI (STEMI) or im-
mediate PCI in non-STEMI or ad hoc PCI in stable dis-
ease a loading dose of 600 mg should be considered 
(grade I C). After bare-metal-stent implantation, clopi-
dogrel should be administered for at least 3–4 weeks 
(grade I A), and after implantation of drug-eluting 
stents for 6–12 months (grade I C). After non-ST eleva-
tion ACS, a prolonged therapy for 9–12 months is rec-
ommended (grade I B).
Glycoprotein (GP) IIb/IIIa Receptor Antagonists
Unlike antiplatelet agents that target only one of many 
individual pathways involved in platelet aggregation, in-
hibitors of the platelet GP IIb/IIIa receptor potently in-
hibit the final common pathway involved in platelet ad-
hesion, activation, and aggregation, by blocking platelet 
binding of fibrinogen [16]. Three GP IIb/IIIa inhibitors 
are currently used as adjunctive treatment in the setting 
of PCI, including the murine-human chimeric antibody 
abciximab, the synthetic nonpeptide tirofiban, and the 
synthetic peptide eptifibatide. Safety and efficacy of ab-
ciximab have initially been tested in randomized place-
bo-controlled trials of balloon angioplasty (EPIC, EPI-
LOG), coronary artery stenting (EPISTENT), and in re-
fractory unstable angina (CAPTURE) [17–20]. While 
the individual studies demonstrated a significant reduc-
tion of ischemic events (i.e., death, MI, urgent revascular-
ization) associated with the drug, a pooled analysis of the 
trials demonstrated even a long-term survival benefit 
(Figure 3) [21]. Side effects include bleeding events, with 
a major bleeding rate ranging from 0.7% to 14% accord-
ing to heparin dose [22], and in up to 1% profound throm-
bocytopenia (< 20,000/µl) [17]. Because of the low plasma 
levels of unbound abciximab, the drug’s inhibitory effect 
can rapidly be reversed by platelet transfusions.
Tirofiban was studied in angioplasty (RESTORE) 
and in unstable angina patients initially treated medi-
cally (PRISM, PRISM-PLUS) [23–25]. Eptifibatide un-
derwent large-scale clinical trial testing in the setting of 
medical management of unstable angina (PURSUIT) 
and PCI (IMPACT-II, ESPRIT) [26–28]. Since the ep-
tifibatide dose used in the initial trials was believed to be 
insufficient to provide adequate GP IIb/IIIa inhibition 
during PCI, the ESPRIT trial evaluated a double-bolus 
regimen (two 180-µg/kg boluses administered 10 min 
apart, followed by an infusion of 2.0 µg/kg/min for 18–24 
h) and demonstrated a benefit in the composite primary 
endpoint of death, MI, urgent TVR within 48 h (10.5% 
vs. 6.6%; p = 0.0015). Based on these results, this eptifi-
batide regimen has become standard. Since for both ti-
rofiban and eptifibatide the number of unbound drug 
molecules in the circulation is very high, platelet trans-
fusions are not effective in reversing the antiplatelet 
properties of these drugs. The mean plasma half-life of 
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Figure 3. Cumulative mortality curves at 3 years in the EPIC, EPILOG, 
and EPISTENT trials showing a statistically significant benefit in favor 
of abciximab (odds ratio 0.78; p = 0.03) [21].
Abbildung 3. Kumulative Mortalitätskurven nach 3 Jahren der EPIC-, 
EPILOG- und EPISTENT-Studien. Die zu Abciximab randomisierten Pati-
enten hatten eine signifikante Mortalitätsreduktion (Odds-Ratio 0,78; 
p = 0,03) [21].
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tirofiban is approximately 2 h, which is slightly shorter 
than that of eptifibatide. The clinical antiplatelet effect 
of these agents is abolished after approximately 4 h of 
drug discontinuation.
Elective Percutaneous Coronary Intervention
GP IIb/IIIa antagonists have been proven to be effec-
tive in reducing ischemic events in patients undergoing 
PCI across a wide variety of coronary lesions and risk 
profiles [29]. The only subgroup of patients not deriving 
benefit from these agents were those undergoing ve-
nous bypass grafting [30]. The likely explanation for the 
lack of efficacy is that the amount and/or the composi-
tion of the material embolized during PCI of bypass 
graft lesions may overwhelm the capacity of these agents 
to protect the distal vasculature. With respect to wheth-
er one agent may be superior to another, the only 
head-to-head comparison (TARGET) demonstrated 
that among 4,809 patients abciximab significantly re-
duced 30-day ischemic events (death, nonfatal MI, or 
urgent TVR) compared with tirofiban (6.0% vs. 7.6%; 
p = 0.038) [31]. Subsequent studies have suggested that 
the level of platelet inhibition at the time of PCI con-
veyed by tirofiban as dosed in TARGET (10-µg/kg bo-
lus followed by a 0.15-µg/kg/min infusion) was insuffi-
cient [32]. A higher tirofiban dose (bolus of 25 µg/kg 
followed by infusion of 0.15 µg/kg/min), proven to be 
efficacious in a pilot study of high-risk patients [33], is 
currently being tested against abciximab in > 8,000 pa-
tients in the US-based TENACITY trial.
In patients pretreated with dual antiplatelet therapy 
(i.e., aspirin and clopidogrel) undergoing PCI, the benefit 
of additional application of GP IIb/IIIa antagonists has 
recently been questioned. The ISAR-REACT trial en-
rolled 2,159 low-risk patients undergoing elective PCI 
[34]. The patients received a loading dose of 600 mg of 
clopidogrel on top of aspirin at least 2 h prior to PCI, and 
then were randomized to abciximab or placebo. The pri-
mary endpoint (death, MI, or urgent revascularization) 
did not differ between the two groups at 30 days, while 
the abciximab-treated patients had more bleeding com-
plications. Importantly, the trial excluded patients at 
higher risk such as those recovering from MI, with ACS, 
insulin-dependent diabetics, and patients with impaired 
left ventricular function. In addition, randomization oc-
curred after coronary angiography, likely excluding pa-
tients with high-risk coronary anatomy. This resulted in 
an unusually low event rate (4% death, MI, or urgent 
revascularization at 30 days). In addition, since the 
ISAR-REACT trial was powered to test superiority and 
not noninferiority, it cannot be concluded that the two 
strategies were equivalent. Despite the limitations, the 
trial demonstrates that, in a properly selected low-risk 
population pretreated with high-dose clopidogrel, PCI 
can be safely performed without GP IIb/IIIa blockers.
Non-ST Elevation Acute Coronary Syndromes
In patients with non-ST elevation ACS treated mainly 
medically, the overall benefit of GP IIb/IIIa inhibitors 
has been modest, as demonstrated by a relative risk re-
duction of 9% documented in a meta-analysis involving 
> 29,000 patients [35]. Nevertheless, in the same study, a 
statistically significant 26% reduction in 30-day death or 
MI was identified among patients who underwent PCI, 
supporting previous findings of the CAPTURE trial that 
demonstrated high efficacy in ischemic event reduction 
associated with these agents among patients with ACS 
undergoing PCI [36]. Additional subsets of ACS patients 
who derive the greatest benefit from GP IIb/IIIa block-
ade include those presenting with positive troponin [36] 
and those with diabetes, as described below.
Acute Myocardial Infarction
The CADILLAC trial assigned 2,082 patients with 
STEMI to balloon angioplasty alone, balloon angioplas-
ty plus abciximab, stenting alone, or stenting plus abcix-
0.1 0.2 0.5 1 2 5 10
ACE
ADMIRAL
CADILLAC balloon
CADILLAC stent
ISAR-2
Petronio et al.
RAPPORT
Favors abciximab Favors control
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95% Cl
Figure 4. Meta-analysis of all six placebo-controlled abciximab trials 
in percutaneous coronary intervention for ST elevation myocardial in-
farction (n = 3,755). The use of abciximab was associated with a sig-
nificant reduction of death (odds ratio [OR] 0.70, 95% confidence inter-
val [CI] 0.50–0.97) [40].
Abbildung 4. Metaanalyse von allen sechs plazebokontrollierten Abci-
ximabstudien während perkutaner Koronarintervention bei akutem 
Herzinfarkt (n = 3 755). Zu Abciximab randomisierte Patienten hatten 
eine signifikante Mortalitätsreduktion (Odds-Ratio [OR] 0,70, 95%-
Konfidenzintervall [CI] 0,50–0,97) [40].
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imab [37]. The use of abciximab had little effect on the 
6-month primary endpoint (composite of death, MI, dis-
abling stroke, and TVR). The event rate was 20.0% 
among patients after balloon angioplasty, 16.5% after 
balloon angioplasty plus abciximab, 11.5% after stent-
ing, and 10.2% after stenting plus abciximab (p = 0.001). 
The ADMIRAL trial randomly assigned 300 STEMI 
patients to abciximab or placebo and the study drug was 
administered in the ambulance prior to hospital admis-
sion [38]. At 30 days, the primary endpoint (composite 
of death, MI, or urgent TVR) occurred in 6.0% of the 
patients in the abciximab group 
compared with 14.6% of those in the 
placebo group (p = 0.01). At 6 
months, the event rate was 7.4% and 
15.9%, respectively (p = 0.02). The 
diverging outcomes of the two stud-
ies are most likely the result of dif-
ferent population enrollment. Ac-
cordingly, the 30-day mortality in 
the CADILLAC trial was 1.1–2.7%, 
while in the ADMIRAL trial it was 
5–10%. Importantly, in the CADIL-
LAC trial patients were randomized 
following coronary angiography, 
thereby likely excluding patients 
with high-risk coronary anatomy, 
while in ADMIRAL allocation oc-
curred prior to angiography. Anoth-
er study, the ACE trial, compared 
stenting versus stenting plus abcix-
imab in 400 patients with STEMI. At 
1 year, the survival rate was 95.2% in 
the abciximab group and 88.2% in 
the stent-alone group (p = 0.017) 
[39]. A recent meta-analysis summa-
rizing the results of all six place-
bo-controlled abciximab trials in 
primary PCI (n = 3,755) demonstrat-
ed that the use of this potent platelet 
inhibitor was associated with a sta-
tistically significant mortality reduc-
tion at 6 months (odds ratio 0.70, 
95% confidence interval 0.50–0.97; 
Figure 4) [40]. From a safety per-
spective, abciximab was associated 
with an overall 39% increased risk 
of major bleedings. The risk was 
driven by patients allocated to high 
heparin doses (100-U/kg bolus followed by a mainte-
nance infusion), while those receiving 70-U/kg bolus 
and no infusion had no statistically increased bleeding 
risk. No large-scale randomized study has addressed the 
use of small molecules in the setting of acute MI.
Glycoprotein IIb/IIIa Receptor Inhibitors 
in Diabetics
The currently available bulk of data concordantly sug-
gests that diabetic patients derive a preferential benefit 
from GP IIb/IIIa inhibitors compared with nondiabet-
Figure 5. Meta-analysis of the placebo-controlled trials of glycoprotein IIb/IIIa receptor inhibi-
tors in the medical management of non-ST elevation acute coronary syndromes. Odds ratio 
with 95% confidence intervals (CI) and corresponding p-values for treatment effect on 30-day 
mortality among diabetic patients [44].
Abbildung 5. Metaanalyse der plazebokontrollierten Studien mit Glykoprotein-IIb/IIIa-Rezep-
tor-Antagonisten in der medikamentösen Behandlung des akuten Koronarsyndroms ohne 
ST-Hebung. Dargestellt ist die 30-Tage-Mortalität bei Diabetikern [44].
Trial n Odds ratio & 95% Cl Placebo IIb/IIIa
PURSUIT 2,163 p = 0.33 6.1% 5.1%
PRISM 687 p = 0.07 4.2% 1.8%
PRISM-PLUS 362 p = 0.17 6.7% 3.6%
GUSTO IV 1,677 p = 0.022 7.8% 5.0%
PARAGON A 412 
p =0.51
 6.2% 4.6%
PARAGON B 1,157 
p = 0.93
 4.8% 4.9%
Pooled 6,458 p = 0.007 6.2% 4.6%
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Figure 6. Odds ratio with 95% confidence intervals (CI) for treatment effect on 30-day mortal-
ity among diabetic patients with acute coronary syndromes undergoing percutaneous coro-
nary intervention. Values to the left of 1.0 indicate a survival benefit of platelet glycoprotein 
IIb/IIIa inhibition [44].
Abbildung 6. 30-Tage-Mortalitätsreduktion durch Glykoprotein-IIb/IIIa-Antagonisten bei dia-
betischen Patienten mit akutem Koronarsyndrom, die einer perkutanen Koronarintervention 
unterzogen wurden [44].
Trial n Odds ratio & 95% Cl Placebo IIb/IIIa
PURSUIT 457 p = 0.57 3.3% 2.4%
PRISM 147 p = 0.50 2.5% 0.0%
PRISM-PLUS 107 p = 1.00 1.8% 0.0%
GUSTO IV 239 p = 0.037 6.5% 1.2%
PARAGON A 45 p =0.31 7.1% 0.0%
PARAGON B 284 p = 0.06 4.3% 0.7%
Pooled 1,279 p = 0.002 4.0% 1.2%
0 0.5 1 1.5 2
IIb/IIIa better Placebo better
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ics [41]. A pooled analysis of the early abciximab experi-
ence (EPIC, EPILOG, and EPISTENT) demonstrated 
that diabetic patients undergoing PCI derived a mortal-
ity benefit from these agents, lowering their risk to the 
one of nondiabetics randomized to placebo [42]. With 
respect to whether one agent may be superior to anoth-
er among diabetics undergoing PCI, the only data avail-
able are derived from the TARGET trial. Among 1,117 
diabetic patients, no difference in outcomes was ob-
served up to 1 year, suggesting comparable efficacies 
between tirofiban and abciximab in the diabetic popula-
tion [43]. Also in the setting of ACS, diabetic patients 
derived a greater benefit from GP IIb/IIIa blockade 
than nondiabetics. In a meta-analysis of all large-scale 
clinical trials addressing the use of GP IIb/IIIa antago-
nists among patients with ACS primarily medically 
managed, a statistically significant 26% mortality reduc-
tion at 30 days (p = 0.007) was demonstrated among dia-
betic patients (n = 6,458; Figure 5) [44]. Even more 
striking was the 70% mortality reduction observed 
among the diabetic patients who underwent PCI in these 
trials (p = 0.002; Figure 6). The value of GP IIb/IIIa re-
ceptor inhibitors in diabetic patients pretreated with 
clopidogrel 600 mg has recently been challenged by the 
ISAR-SWEET study [45]. Among 701 diabetic patients 
undergoing elective PCI pretreated with 600 mg of clo-
pidogrel > 2 h prior to the procedure, abciximab was not 
more efficacious than placebo in reducing ischemic 
events. Importantly, ACS patients were excluded from 
the trial. In addition, the trial was underpowered to ad-
dress clinical endpoints. Nevertheless, the study sug-
gests that there is a subset of diabetic patients that, if 
adequately pretreated with clopidogrel, may safely un-
dergo elective PCI even in the absence of GP IIb/IIIa 
receptor inhibitors.
Recommendations According to the 2005 ESC-PCI 
Guidelines
For PCI in stable patients, GP IIb/IIIa antagonists are 
helpful in unstable or complex lesions, as bailout medica-
tion in case of threatening/actual vessel closure, visible 
thrombus or no/slow-reflow phenomenon (grade IIa C) 
[4]. In high-risk non-STEMI patients, if cardiac catheter-
ization is likely to be performed within 2.5 h, GP IIb/IIIa 
antagonists can be postponed and abciximab or eptifiba-
tide initiated in the catheterization laboratory. If cardiac 
catheterization is unlikely to be performed within 2.5 h, 
tirofiban or eptifibatide should be initiated (grade I C). 
In STEMI, abciximab is beneficial (grade IIa A).
Conclusion
Aspirin remains the cornerstone of any antithrombotic 
regimen in the interventional setting. The addition of a thi-
enopyridine is mandatory following stenting to prevent 
thrombosis of the device. Whenever possible, patients un-
dergoing PCI should be pretreated with clopidogrel and 
the drug should be continued for up to 1 year. GP IIb/IIIa 
antagonists should be administered in high-risk patients, 
such as those with acute coronary syndromes, diabetes, or 
complex coronary anatomy.
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